Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial

Table 2 Changes in parameters from baseline to 24 weeks in each sub-group after adjusting for the baseline values of each variable

Outcome	Ipragliflozin group	Control group	Group difference (95% CI)	P-value
Change in LAVi (mL/m²)	0.28 ± 9.03	1.79 ± 9.42	− 1.46 (− 5.31 to 2.40)	0.452
Change in LVEF (%)	1.84 ± 6.18	0.66 ± 7.02	0.83 (− 2.29 to 3.96)	0.595
Change in TMF-E (cm/s)	− 1.63 ± 16.32	0.67 ± 10.24	− 1.26 (− 8.50 to 5.98)	0.728
Change in e’ (cm/s)	0.71 ± 1.89	− 0.38 ± 3.56	0.71 (− 0.49 to 1.92)	0.239
Change in E/e’ ratio	− 0.93 ± 3.15	0.21 ± 3.17	− 0.82 (− 2.44 to 0.81)	0.317

Data are expressed as the mean ± standard deviation
CI, confidence interval; E/e’, maximum early diastolic velocity to average early diastolic peak velocity; e’, average of the early diastolic peak velocity; LAVi, left atrial volume index; LVEF, left ventricular ejection fraction; TMF-E, early diastolic trans-mitral flow

ISSN: 1475-2840